Rapamycin (Sirolimus)
ra-pa-MY-sin
IUPAC Sirolimus (rapamycin)
SMILES
C[C@@H]1CC[C@H]2C[C@H](/C(=C/C=C/C=C/[C@@H](C[C@@H](C(=O)[C@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
C+
52.0/100
Evidence Summary
Rapamycin has the strongest preclinical lifespan extension data of any compound — consistent results across yeast, worms, flies, and mice, including the ITP (Interventions Testing Program) gold-standard studies.
However, human evidence remains thin. The PEARL trial (150 participants, 1 year) showed modest biomarker changes. A 2025 systematic review concluded insufficient evidence to recommend rapamycin for healthy adults. The gap between preclinical promise and clinical evidence is significant.
The protein-rapamycin mTOR tension is the most complex dose-governance question in longevity medicine: rapamycin inhibits mTOR, which is also the pathway through which dietary protein stimulates muscle growth.
However, human evidence remains thin. The PEARL trial (150 participants, 1 year) showed modest biomarker changes. A 2025 systematic review concluded insufficient evidence to recommend rapamycin for healthy adults. The gap between preclinical promise and clinical evidence is significant.
The protein-rapamycin mTOR tension is the most complex dose-governance question in longevity medicine: rapamycin inhibits mTOR, which is also the pathway through which dietary protein stimulates muscle growth.
Safety Considerations
Immunosuppression at transplant doses. Mouth ulcers and stomatitis common. Hyperlipidemia. Impaired wound healing. Off-label longevity dosing (weekly, low-dose) has limited safety data. Contraindicated in immunocompromised individuals, active infections, pre-surgical patients.
Evidence Signals (0)
Known Interactions (2)
Products Containing Rapamycin (Sirolimus)
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.